Welcome to our dedicated page for ANGIODYNAMICS SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANGIODYNAMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANGIODYNAMICS's regulatory disclosures and financial reporting.
AngioDynamics reported fiscal Q3 2026 results showing solid Med Tech–led growth but continued GAAP losses. Net sales were $78.4 million, up 8.9% year over year, with Med Tech revenue of $37.3 million growing 19.0% and Med Device revenue of $41.1 million up 1.1%.
Gross margin was 52.9%, down 110 basis points, reflecting tariffs, inflation and manufacturing transition costs. The company posted a GAAP net loss of $8.1 million, or ($0.19) per share, and a pro forma adjusted net loss of $3.0 million, or ($0.07) per share, while pro forma adjusted EBITDA improved to $1.8 million.
AngioDynamics ended the quarter with $37.8 million in cash and no debt. It raised full-year 2026 guidance, now expecting net sales of $313.5–$315.5 million, Med Tech growth of 15–17%, adjusted EBITDA of $10.0–$12.0 million, and adjusted EPS between ($0.30) and ($0.23).
AngioDynamics Inc amendment shows The Vanguard Group reports 0 shares of Common Stock beneficially owned, representing 0% of the class as stated in the filing. The amendment explains an internal realignment effective January 12, 2026, leading Vanguard and certain subsidiaries to report holdings separately.
AngioDynamics, Inc. received an amended Schedule 13G/A from Divisadero Street Capital Management and related entities, along with William Zolezzi, reporting a very small passive position in its common stock. The group reports beneficial ownership of 4,576 shares, representing 0.01% of AngioDynamics’ outstanding common stock.
The filing shows no sole voting or dispositive power over the shares; all reported power is shared among the reporting persons. All of the securities are directly owned by advisory clients of Divisadero Street Capital Management, and each reporting person disclaims beneficial ownership beyond any pecuniary interest.
The group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics, and that overall ownership remains at or below 5% of the class.
Systematic Financial Management filed a Schedule 13G reporting a passive ownership stake in AngioDynamics Inc. common stock. The firm beneficially owns 2,508,295 shares, representing 6.05% of the outstanding common stock, with sole voting power over 1,478,345 shares and sole dispositive power over all 2,508,295 shares.
The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AngioDynamics. The reported holdings relate to AngioDynamics common stock with CUSIP 03475V101.
Kevin Kotler has filed a Schedule 13G reporting beneficial ownership of 2,421,526 shares of AngioDynamics, Inc. common stock, representing 5.9% of the class as of 01/06/2026. He holds sole voting and dispositive power over these shares and reports the stake as passive, not for influencing control.
The filing notes that 313,495 shares are owned in his individual capacity, while the remainder is held in accounts he manages. He also formally disclaims beneficial ownership beyond his pecuniary interest in the reported securities.
AngioDynamics outlined a planned leadership transition and retention program for senior executives. President and CEO James C. Clemmer signed a Transition and Retirement Agreement under which he will continue as CEO until a successor is appointed or until November 30, 2026, with possible month‑to‑month extensions by mutual agreement. His existing stock options and service-based restricted stock units will continue to vest until his service as a consultant or director ends, after which they immediately vest, while performance-based restricted stock units may still vest according to their original terms. The board also approved retention agreements for the executive leadership team: key named executive officers are eligible for cash retention awards equal to 150% of base salary and others for 50% of base salary, if they remain employed until the earlier of six months after the new CEO starts or June 1, 2027.
AngioDynamics, Inc. filed a current report after its President and CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. The company has made the conference presentation slides available as Exhibit 99.1, furnishing them for informational purposes.
The report clarifies that these slides are furnished rather than filed, meaning they are not subject to certain liability provisions and are not automatically incorporated into other securities filings. It also includes a detailed caution about forward-looking statements, noting that expectations about strategy, products, financial position and growth are subject to numerous risks, including regulatory actions, economic conditions, competition, supply chain challenges and factors described in prior AngioDynamics SEC reports.
AngioDynamics, Inc. received an updated large-shareholder disclosure showing that investment entities affiliated with Millennium reported modest, passive stakes in its common stock. Integrated Core Strategies (US) LLC reported beneficial ownership of 551,565 shares, representing 1.3% of AngioDynamics’ common stock. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 842,548 shares, or 2.0% of the outstanding common stock, as of the event date of 12/31/2025. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics.
AngioDynamics, Inc. reported stockholder voting results. Shareholders elected two directors: James C. Clemmer received 29,634,152 votes for and 800,454 withheld, with 5,462,943 broker non-votes; Michael E. Tarnoff, MD received 29,245,896 votes for and 1,188,710 withheld, with 5,462,943 broker non-votes.
Stockholders also approved two additional items. One item received 35,727,186 votes for, 156,899 against, and 13,464 abstentions; there were no broker non-votes for this item. Another item received 28,357,782 votes for, 2,057,982 against, 18,842 abstentions, and 5,462,943 broker non-votes.
AngioDynamics (ANGO) reported an insider open‑market purchase. On 10/21/2025, an officer serving as SVP, Chief Legal Officer bought 10,000 shares of common stock, coded “P” for purchase. The weighted average price was $11.81, with trades executed between $11.71 and $11.90. After this transaction, the reporting person beneficially owned 93,597 shares, held directly. The filing notes the weighted‑average pricing and that detailed trade‑by‑trade data within the price range is available upon request.